Apellis Pharmaceuticals just raised $33M to fund exploring its immunotherapy platform in three disparate indications – disease of the bone marrow, the lungs and the eye.
The round, which is a private placement of its Series C preferred stock, was led by Morningside Ventures, AJU IB Investment Co. and Epidarex Ventures. The indications are:
-Paroxysmal nocturnal hemoglobinuria, a rare bone marrow disease in which the body’s immune system attacks its own red blood cells. Apellis’ drug candidates inhibit the C3 complement factor, a protein that’s known to cause inflammation
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
-COPD. Apellis thinks the same C3 inhibitor could slow down the progression of this chronic lung disease.
-Apellis’ APL-2 is being tested in patients with retinal lesions that stem from dry age-related macular degeneration – a condition with no current approved therapy.
“We are excited to test the immense potential of complement immunotherapy,” CEO Cedric Francois said in a statement. “Our clinical programs are designed to be implemented in short periods of development, with a robust regulatory strategy, innovative clinical designs and product profiles that could change the lives of millions of patients affected by auto-immunity.”
